Tyra Biosciences Inc.
(TYRA)
undefined
undefined%
At close: undefined
15.63
-0.03%
After-hours Jan 03, 2025, 04:00 PM EST
Company Description
Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer.
Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer.
The company is also developing programs targeting FGFR2- intrahepatic cholangiocarcinoma,FGFR3-related achondroplasia, REarranged during transfection kinase, and FGFR4-related cancers.
In addition, the company offers SNAP platform which enable rapid structural design through iterative molecular SNAPshots.
Tyra Biosciences, Inc. was incorporated in 2018 and is based in Carlsbad, California.
Tyra Biosciences Inc.
| Country | United States |
| IPO Date | Sep 15, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 49 |
| CEO | Dr. Todd Harris Ph.D. |
Contact Details
Address: 2656 State Street Carlsbad, California United States | |
| Website | https://www.tyra.bio |
Stock Details
| Ticker Symbol | TYRA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001863127 |
| CUSIP Number | 90240B106 |
| ISIN Number | US90240B1061 |
| Employer ID | 83-1476348 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Todd Harris Ph.D. | Co-Founder, President, Chief Executive Officer, Secretary, Treasurer & Director |
| Alan Fuhrman CPA | Chief Financial Officer |
| Daniel Bensen | Co-Founder & Chief Operating Officer |
| Dr. Robert L. Hudkins Ph.D. | Chief Technology Officer |
| Ali D. Fawaz J.D. | General Counsel |
| Dr. Douglas Warner M.D. | Chief Medical Officer |
| Dr. Piyush R. Patel Ph.D. | Chief Development Officer |
| Dr. Ronald V. Swanson Ph.D. | Chief Scientific Officer |
| Liz Pagano | Senior Vice President of Human Resources |
| Sarah Honig | Vice President of Corporate Development & Strategy |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 06, 2024 | SC 13D/A | [Amend] Filing |
| Nov 26, 2024 | 4 | Filing |
| Nov 19, 2024 | SC 13D/A | [Amend] Filing |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 13, 2024 | SC 13D/A | [Amend] Filing |
| Nov 13, 2024 | 4 | Filing |
| Nov 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 08, 2024 | 4 | Filing |
| Nov 07, 2024 | 10-Q | Quarterly Report |